Nika Pharmaceuticals, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OQB
Nika Pharmaceuticals terminated its engagement with OLAYINKA OYEBOLA & CO and hired Boladale Lawal & Co as its new independent accountant.
OQB
Nika Pharmaceuticals has engaged OLAYINKA OYEBOLA & CO as their new independent accountant, effective September 23, 2024.
OQB
Nika Pharmaceuticals, Inc. has cancelled its acquisition of Nika Pharmaceuticals, Ltd., and its independent accountant has resigned, leading to a search for a new auditor.
OQB
Nika Pharmaceuticals, Inc. has acquired 100% ownership of Nika Pharmaceuticals, Ltd., gaining control of a production facility and land valued at $2.045 million.
OQB
Nika Pharmaceuticals has completed the acquisition of a 40% stake in Nika Europe Ltd., bringing its total ownership to 80%, and acquired four new drug and supplement technologies.
OQB
Nika Pharmaceuticals, Inc. has completed a market extension merger with Nika BioTechnology, Inc., effective March 1, 2024, consolidating operations and streamlining investment.
OQB
Nika Pharmaceuticals has dismissed B F Borgers CPA PC and engaged Fruci & Associates II, PLLC as its new independent accountant, effective February 14, 2024.